Pharmaceuticals

ANI Pharmaceuticals launches a generic version of Carbatrol, aiming for a slice of a $65M market and promising improved patient access for chronic conditions.

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

Biotech firm Epitopea adds top expert Dr. Lisa Butterfield, validating its novel RNA vaccine approach targeting hidden cancer antigens for hard-to-treat tumors.

Endpoint's new RTSM platform update introduces conversational AI and advanced supply chain tools to give sponsors greater control over complex global trials.

A family's personal journey with a rare disorder sparks a major investment in Quiver Bioscience's AI-powered therapy, aiming to treat Dup15q syndrome.

A landmark study reveals 100% tumor control with a personalized radiation therapy, offering profound new hope for patients with inoperable liver cancer.

As women in midlife turn to drugs like Ozempic, a new crisis is emerging: significant muscle loss. A new approach aims to protect metabolic health.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

New data shows Imofinostat turns 'cold' colorectal tumors 'hot' for immunotherapy and breaks chemo-resistance in pancreatic cancer, fueling pivotal trials.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

European digital health firm Apomeds launches in the UK, targeting the booming telehealth market with a focus on discreet, high-demand treatments.

Lupin has launched a generic version of the blockbuster diabetes drug Farxiga, signaling lower costs for patients and a major shake-up in the SGLT2 market.

A new collaboration between Emporia Research and Definitive Healthcare promises unprecedented accuracy in recruiting healthcare decision-makers for vital research.

With a massive $54M Series A, Vivatides Therapeutics aims to solve RNA's biggest delivery problem, unlocking new treatments for a host of chronic diseases.

Jetstream Venture Fund's deals with Surf Therapeutics and Hill Research signal a new era of accessible venture capital backing transformative technologies.

The tech leader will showcase an integrated platform turning supply chain complexity and regulatory hurdles like the Digital Product Passport into a competitive edge.

A new company is selling franchises to doctors and pharmacists, promising to cut out insurers and restore local care. But can this bold model survive the system?

Ditching the static model, CleanSpace is building a full-scale, operational pharmaceutical factory on the tradeshow floor, a move set to transform B2B marketing.